CASI Pharmaceuticals Holdings Inc. Announces Major Divestiture of Chinese Assets

In a significant move within the healthcare sector, CASI Pharmaceuticals Holdings Inc., a company known for its focus on developing and commercializing therapeutics and pharmaceutical products, has entered into a definitive agreement to divest its assets in China. This strategic decision marks a pivotal shift for the company, which operates through subsidiaries in China and has its headquarters in Rockville, Maryland.

On May 12, 2025, CASI Pharmaceuticals announced that it had finalized an Equity and Assets Transfer Agreement with Kaixin Pharmaceuticals Inc., a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, who also serves as the Chairman of the board of directors and CEO of CASI. Under the terms of the agreement, CASI will sell and transfer 100% equity interests in two of its Chinese subsidiaries, along with all associated licensing rights, distribution rights, supply arrangements, and related rights concerning key products such as BI-1206 and CID-103.

The deal, valued at approximately $20 million, signifies a strategic realignment for CASI Pharmaceuticals as it seeks to streamline its operations and focus on its core competencies. The divestiture is expected to provide the company with additional capital to reinvest in its research and development activities, potentially accelerating the development of new therapeutics.

CASI Pharmaceuticals, listed on the Nasdaq stock exchange, has experienced significant fluctuations in its stock price over the past year. As of May 8, 2025, the company’s close price stood at $1.8854, a notable decrease from its 52-week high of $7.67 on September 10, 2024. The recent divestiture could be seen as a strategic move to stabilize the company’s financial position and enhance shareholder value.

The decision to divest its Chinese assets comes at a time when the healthcare sector is undergoing rapid changes, with companies increasingly focusing on innovation and efficiency. By shedding non-core assets, CASI Pharmaceuticals aims to strengthen its market position and enhance its ability to compete in the global pharmaceutical landscape.

As the company moves forward with this strategic divestiture, stakeholders will be closely watching how these changes impact its long-term growth and development. With a market capitalization of approximately $30 million, CASI Pharmaceuticals is poised to leverage this transaction to bolster its financial health and continue its mission of bringing innovative therapeutics to market.

For more information on CASI Pharmaceuticals and its ongoing initiatives, visit their website at www.casipharmaceuticals.com .